Venus Medtech (Hangzhou) (HKSE:02500) Total Receivables: HK$297.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02500 Venus Medtech (Hangzhou) Inc HKSE:02500
52 GF Score
Price HK$1.10
GF Value HK$3.35
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) Total Receivables?

Venus Medtech (Hangzhou) HKSE:02500 -2.65% 52 Total Receivables is HK$297.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.35 (Possible Value Trap). The stock has 4 warning signs investors should review.

Venus Medtech (Hangzhou)'s Total Receivables for the quarter that ended in Dec. 2025 was HK$297.1 Mil.

Venus Medtech (Hangzhou) Total Receivables Related Terms

Venus Medtech (Hangzhou) Total Receivables Historical Data

* Premium members only.

The historical data trend for Venus Medtech (Hangzhou)'s Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Medtech (Hangzhou) Total Receivables Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 417.11 398.38 466.03 353.52 297.15

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 466.03 512.64 353.52 349.35 297.15
HKSE:02500
52GF Score
Venus Medtech (Hangzhou) Inc HKSE:02500
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Medtech (Hangzhou) Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$297.1 Mil mean?
Venus Medtech (Hangzhou) (HKSE:02500) has a Total Receivables of HK$297.1 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Venus Medtech (Hangzhou) and its competitors.
Is Venus Medtech (Hangzhou)'s Total Receivables too high?
Venus Medtech (Hangzhou)'s current Total Receivables is HK$297.1 Mil. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Total Receivables compare to ABT and SYK?
Venus Medtech (Hangzhou)'s Total Receivables of HK$297.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Total Receivables is HK$297.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.35, compared to a current price of HK$1.10 — trading 67.2% below its estimated fair value. The current Total Receivables is HK$297.1 Mil. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Total Receivables is HK$297.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of HK$1.10 is trading 67.2% below its estimated GF Value™ of HK$3.35. GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.

Key valuation signals for HKSE:02500:

  • Total Receivables: HK$297.1 Mil
  • GF Value™: HK$3.35 vs. price of HK$1.10 (67.2% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Medtech (Hangzhou) Business Description

Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for HKSE:02500

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.10
Price
HK$3.35
GF Value